MedTrace Logo

Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial

NCT03007134 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2017-01-02

No results posted yet for this study

Summary

The purpose of this study is to (1) compare a technically improved assay with an existing assay used to measure serum anti-GM-CSF antibodies in stored serum samples previously obtained from patients diagnosed with either primary, secondary, congenital or idiopathic pulmonary alveolar proteinosis (PAP), other chronic diseases or disease-free, healthy individuals; (2) determine the prevalence and levels of anti-GM-CSF autoantibodies and (3) define the breadth of the autoimmune antibody responses in primary PAP patients from the United States, Japan, Australia, and Europe using previously collected serum samples; and (4) using a chart review approach, compare the clinical, radiologic and laboratory features of primary PAP patients to determine if differences exist among patients in these globally geographically distributed regions.

Conditions

  • Pulmonary Alveolar Proteinosis

Interventions

OTHER

Retrospective Chart Review

No intervention.

Sponsors & Collaborators

  • Rare Diseases Clinical Research Network

    collaborator NETWORK

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Bruce Trapnell · Children's Hospital Medical Center, Cincinnati

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2010-07-31
Completion
2011-07-31

Countries

  • United States
  • Germany
  • Italy
  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03007134 on ClinicalTrials.gov